|
||
 HOME- -ABOUT - -TECHNOLOGIES ...PIPELINE - -MANAGEMENT - ...ADVISORY BOARD - -INVESTORS - -CAREERS - -CONTACT |
||
| Innovative Drug Delivery | |
| Nemaura Pharma is a specialty pharmaceutical drug delivery company. We use unique formulation strategies using micro and nano technologies to develop products that will deliver a wide range of drugs safely, and more effectively. Nemaura's lead products are transdermal systems which allow drug dosages to be tailored to individual patient needs, provide on-demand therapy, and minimally-invasive diagnostics. Our patented formulation technologies are used in combination with the transdermal systems for the needle-free delivery of drugs through the skin. The technologies provide a platform for the reformulation of a wide range of drug molecules for more effective human administration. Our innovative development programs will lead to significantly improved healthcare and patient management. |
| LATEST NEWS | ||
| June 2007: £0.5 Million development program launched by Nemaura Pharma to develop a clinical prototype of their patented Memspatch® Transdermal drug delivery system, for chronotherapy, and on demand drug delivery, with a focus on pain management.
May 2008: Nemaura Pharma announce a £1.3 Million research and development program to develop their proprietary novel transdermal patch technology for non-invasive diagnostics and patient monitoring, in collaboration with the University of Nottingham and DataLink electronics. March 2009: Nemaura pharma raises £350,000 to fund early prototype development of its unique patent pending microneedle technology platform. August 2009: Nemaura licenses its rapid penetrating gel platform technology to a UK Pharma Company for an undisclosed indication. January 2011: Nemaura Pharma relocates its R&D laboratories to purpose built laboratories at Holywell Park, Loughborough, UK. March 2011: £1.2m additional private equity investment raised by Nemaura from its existing shareholders to support its ongoing pre-clinical and clinical programs. July 2011: £250,000 Technology Strategy Board grant awarded to Nemaura Pharma for developing a clinical prototype of its non-invasive transdermal patch technology. September 2011: Nemaura licenses its matrix patch technology for an undisclosed indication to a Global generics company, for upfront, milestone and royalty payments. October 2011: A UK Multi-national Pharma company engages in the pre-clinical evaluation of Nemaura’s rapid-acting transdermal gel technology for an undisclosed indication. |
HOME | ABOUT | TECHNOLOGIES | PIPELINE | MANAGEMENT Registered Name: Nemaura Pharma Limited |
||